In a patient with chronic kidney disease stage 3 (estimated glomerular filtration rate ≈ 48 mL/min/1.73 m², serum creatinine ≈ 120 µmol/L), which lipid‑lowering medication is preferred: fenofibrate or ezetimibe?

Ezetimibe is Preferred Over Fenofibrate in CKD Stage 3

In a patient with CKD stage 3 (eGFR 48 mL/min/1.73 m²), ezetimibe should be used as the lipid-lowering agent, not fenofibrate. The primary goal is cardiovascular risk reduction through LDL-cholesterol lowering, and fenofibrate poses significant risks of worsening renal function in this population.

The Evidence-Based Rationale

Guideline-Directed Therapy Supports Ezetimibe

The KDIGO 2013 guidelines provide a strong (1A) recommendation that adults ≥50 years with eGFR <60 mL/min/1.73 m² should receive either a statin or statin/ezetimibe combination 1. This recommendation is based on the landmark SHARP trial, which demonstrated that simvastatin-ezetimibe combination therapy reduced major atherosclerotic events (coronary death, MI, stroke, or revascularization) in patients with CKD stages G3a-G5 1.

Critically, fenofibrate is not mentioned as a recommended therapy in CKD patients in these guidelines. The focus is entirely on statin-based therapy with or without ezetimibe for cardiovascular risk reduction 1.

Fenofibrate's Problematic Renal Effects

Fenofibrate consistently raises serum creatinine and reduces eGFR in CKD patients, which is particularly concerning at your patient's baseline eGFR of 48:

• Acute creatinine elevation: Fenofibrate causes rapid (within 2-4 weeks) increases in serum creatinine, often 20-30% or more 2, 3, 4. In one case report, a patient with stage 4 CKD experienced a 62% increase in creatinine, with eGFR dropping from 24.8 to 13 mL/min/1.73 m², requiring preparation for dialysis 4.

• Risk factors for creatinine elevation: Your patient's eGFR of 48 places them at increased risk, as impaired baseline renal function is a key predictor of fenofibrate-associated creatinine rises 3.

• Reversibility concerns: While some studies suggest creatinine increases may be reversible upon discontinuation 2, 3, this creates unnecessary risk and complexity. In the prospective study by 2, only 59% of patients showed ≥30% eGFR improvement at 3 months after stopping fenofibrate, and this persisted in only 45-50% at 6-12 months.

Ezetimibe's Safety Profile in CKD

Ezetimibe demonstrates excellent safety and efficacy in CKD stage 3:

• Effective LDL reduction: In CKD patients, ezetimibe produces mean LDL reductions of 27.0% and non-HDL reductions of 24.8% 5—actually greater than in non-CKD patients (23.5% and 21.7% respectively).

• No dose adjustment needed: The FDA label confirms ezetimibe can be administered at standard 10 mg daily dosing without adjustment for renal impairment 6.

• Comparable safety: Muscle-related adverse events occurred in 13.9% of both CKD and non-CKD patients, indicating no increased risk despite potential drug accumulation 5.

The Clinical Decision Algorithm

For your patient with CKD stage 3 (eGFR 48):

1. If not on a statin: Start a statin first (guideline-directed therapy) 1
2. If already on maximum tolerated statin but LDL not at goal: Add ezetimibe 10 mg daily 1
3. If statin-intolerant: Use ezetimibe 10 mg daily as monotherapy 1
4. Avoid fenofibrate unless there is severe hypertriglyceridemia (>500 mg/dL) with pancreatitis risk—and even then, use with extreme caution and close monitoring 3

Key Pitfalls to Avoid

• Don't use fenofibrate for routine dyslipidemia management in CKD stage 3: The cardiovascular benefit in CKD comes from LDL lowering (statins/ezetimibe), not triglyceride lowering 1.

• Don't be misled by potential "renoprotective" effects of fenofibrate: While one observational study 7 suggested reduced ESRD risk with fenofibrate, this contradicts the well-established acute creatinine-raising effects 2, 3, 4 and lacks support from high-quality RCTs in the CKD population.

• Monitor appropriately: If ezetimibe is added to a statin, perform liver enzyme testing as clinically indicated 6. Assess LDL-C as early as 4 weeks after initiation 6.

• Timing with bile acid sequestrants: If your patient is on cholestyramine, administer ezetimibe ≥2 hours before or ≥4 hours after the sequestrant 6.

The evidence unequivocally supports ezetimibe over fenofibrate for lipid management in your CKD stage 3 patient, prioritizing both cardiovascular benefit and renal safety.